SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Adolfsson Jan) srt2:(2010-2014)"

Sökning: WFRF:(Adolfsson Jan) > (2010-2014)

  • Resultat 1-10 av 58
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bratt, Ola, et al. (författare)
  • Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease : a population-based study from the National Prostate Cancer Register of Sweden
  • 2010
  • Ingår i: Scandinavian Journal of Urology and Nephrology. - : Informa Healthcare. - 0036-5599 .- 1651-2065. ; 44:6, s. 384-390
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. To investigate the effects of prostate-specific antigen (PSA) testing of men without clinical signs of prostate cancer on the incidence of prostate cancer in Sweden. Material and methods. Information on the cause of diagnosis, tumour characteristics and primary treatment for patients diagnosed with prostate cancer between January 1999 and December 2007 was extracted from the National Prostate Cancer Register of Sweden. This register includes data for 95% of Swedish prostate cancer cases. Results. The total age-standardized annual incidence of prostate cancer per 100 000 men increased from 187 in 1999 to 233 in 2004, but decreased thereafter to 196 in 2007. The incidence of asymptomatic cases also peaked in 2004 (at 62 per 100 000 men), but varied six-fold between different counties in that year (16–98 per 100 000 men). Asymptomatic cases (n = 17 143) constituted 15% of all new cases in 2000 and 30% in 2007. Almost as many cases were diagnosed in stage T1c in men with symptoms, usually from the lower urinary tract. Together these two groups constituted 29% of all new cases in 2000 and 52% in 2007. It was estimated that at least one-third of all Swedish men aged 50–75 years had a PSA test between 2000 and 2007. Conclusions. Even though screening for prostate cancer is not recommended in Sweden, PSA testing of men without clinical signs of prostate cancer is common. The effects on the Swedish incidence of prostate cancer were similar to those reported from the USA.
  •  
2.
  •  
3.
  • Norenstedt, Sophie, et al. (författare)
  • Breast cancer associated with primary hyperparathyroidism : a nested case control study
  • 2011
  • Ingår i: Clinical Epidemiology. - 1179-1349 .- 1179-1349. ; 3, s. 103-106
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Primary hyperparathyroidism (pHPT) is associated with an increased risk of developing breast cancer, but little is known about the underlying factors. The aim of this study was to compare women with a history of pHPT and a reference population in terms of standard factors predictive of prognosis and response to therapy for breast cancer. METHODS: We analyzed data collected from the National Swedish Cancer Register and from two regional oncologic center registries. Seventy-one women with breast cancer and a history of parathyroid adenomectomy were compared with 338 matched controls with breast cancer only. Tumor size, stage, hormone receptor status, lymph node status, cause of death, and cumulative survival were analyzed. RESULTS: The mean age was 69 ± 11 years (95% confidence interval [CI]: 68-70) in both groups and the mean time interval between the parathyroid surgery and breast cancer diagnosis was 91 ± 68 months (95% CI: 72-111). There were no differences between the two groups regarding size, stage, lymph node metastases, or survival, but none of the cases with a history of pHPT were found in Stage III or IV. CONCLUSION: In conclusion, factors predictive of prognosis and response to therapy in women with a history of pHPT and breast cancer are similar to those in breast cancer patients without pHPT.
  •  
4.
  • Stattin, Pär, et al. (författare)
  • Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
  • 2010
  • Ingår i: Journal of the National Cancer Institute. - : Oxford University Press (OUP). - 1460-2105 .- 0027-8874. ; 102:13, s. 950-8
  • Tidskriftsartikel (refereegranskat)abstract
    • Treatment for localized prostate cancer remains controversial. To our knowledge, there are no outcome studies from contemporary population-based cohorts that include data on stage, Gleason score, and serum levels of prostate-specific antigen (PSA).
  •  
5.
  • Tilling, Kate, et al. (författare)
  • Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer : a comparison of observational cohorts
  • 2010
  • Ingår i: European Urology. - : Elsevier BV. - 0302-2838 .- 1873-7560. ; 57:3, s. 446-452
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Prostate-specific antigen (PSA) measurements are increasingly used to monitor men with localised prostate cancer (PCa), but there is little consensus about the method to use. OBJECTIVE: To apply age-specific predictions of PSA level (developed in men without cancer) to one cohort of men with clinically identified PCa and one cohort of men with PSA-detected PCa. We hypothesise that among men with clinically identified cancer, the annual increase in PSA level would be steeper than in men with PSA-detected cancer. DESIGN, SETTING, AND PARTICIPANTS: The Scandinavian Prostate Cancer Group 4 (SPCG-4) cohort consisted of 321 men assigned to the watchful waiting arm of the SPCG-4 trial. The UK cohort consisted of 320 men with PSA-detected PCa in the Prostate testing for cancer and Treatment (ProtecT) study who opted for monitoring. Multilevel models describing changes in PSA level were fitted to the two cohorts, and average PSA level at age 50, change in PSA level with age, and predicted PSA values were derived. MEASUREMENTS: PSA level. RESULTS AND LIMITATIONS: In the SPCG-4 cohort, mean PSA at age 50 was similar to the cancer-free cohort but with a steeper yearly increase in PSA level (16.4% vs 4.0%). In the UK cohort, mean PSA level was higher than that in the cancer-free cohort (due to a PSA biopsy threshold of 3.0 ng/ml) but with a similar yearly increase in PSA level (4.1%). Predictions were less accurate for the SPCG-4 cohort (median difference between observed and predicted PSA level: -2.0 ng/ml; interquartile range [IQR]: -7.6-0.7 ng/ml) than for the UK cohort (median difference between observed and predicted PSA level: -0.8 ng/ml; IQR: -2.1-0.1 ng/ml). CONCLUSIONS: In PSA-detected men, yearly change in PSA was similar to that in cancer-free men, whereas in men with symptomatic PCa, the yearly change in PSA level was considerably higher. Our method needs further evaluation but has promise for refining active monitoring protocols.
  •  
6.
  • Van Hemelrijck, Mieke, et al. (författare)
  • Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0
  • 2013
  • Ingår i: International Journal of Epidemiology. - Oxford : Oxford University Press (OUP): Policy B - Oxford Open Option D. - 0300-5771 .- 1464-3685. ; 42:4, s. 956-967
  • Tidskriftsartikel (refereegranskat)abstract
    • In 1987, the first Regional Prostate Cancer Register was set up in the South-East health-care region of Sweden. Other health-care regions joined and since 1998 virtually all prostate cancer (PCa) cases are registered in the National Prostate Cancer Register (NPCR) of Sweden to provide data for quality assurance, bench marking and clinical research. NPCR includes data on tumour stage, Gleason score, serum level of prostate-specific antigen (PSA) and primary treatment. In 2008, the NPCR was linked to a number of other population-based registers by use of the personal identity number. This database named Prostate Cancer data Base Sweden (PCBaSe) has now been extended with more cases, longer follow-up and a selection of two control series of men free of PCa at the time of sampling, as well as information on brothers of men diagnosed with PCa, resulting in PCBaSe 2.0. This extension allows for studies with case-control, cohort or longitudinal case-only design on aetiological factors, pharmaceutical prescriptions and assessment of long-term outcomes. The NPCR covers andgt; 96% of all incident PCa cases registered by the Swedish Cancer Register, which has an underreporting of andlt; 3.7%. The NPCR is used to assess trends in incidence, treatment and outcome of men with PCa. Since the national registers linked to PCBaSe are complete, studies from PCBaSe 2.0 are truly population based.
  •  
7.
  •  
8.
  •  
9.
  • Adolfsson, Emelie, et al. (författare)
  • Response of lithium formate EPR dosimeters at photon energies relevant to the dosimetry of brachytherapy
  • 2010
  • Ingår i: Medical physics (Lancaster). - : American Association of Physicists in Medicine. - 0094-2405. ; 37:9, s. 4946-4959
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE:To investigate experimentally the energy dependence of the detector response of lithium formate EPR dosimeters for photon energies below 1 MeV relative to that at 60Co energies. High energy photon beams are used in calibrating dosimeters for use in brachytherapy since the absorbed dose to water can be determined with high accuracy in such beams using calibrated ion chambers and standard dosimetry protocols. In addition to any differences in mass-energy absorption properties between water and detector, variations in radiation yield (detector response) with radiation quality, caused by differences in the density of ionization in the energy imparted (LET), may exist. Knowledge of an eventual deviation in detector response with photon energy is important for attaining high accuracy in measured brachytherapy dose distributions.METHODS:Lithium formate EPR dosimeters were irradiated to known levels of air kerma in 25-250 kV x-ray beams and in 137Cs and 60Co beams at the Swedish Secondary Standards Dosimetry Laboratory. Conversions from air kerma free in air into values of mean absorbed dose to the detectors were made using EGSnrc MC simulations and x-ray energy spectra measured or calculated for the actual beams. The signals from the detectors were measured using EPR spectrometry. Detector response (the EPR signal per mean absorbed dose to the detector) relative to that for 60Co was determined for each beam quality.RESULTS:Significant decreases in the relative response ranging from 5% to 6% were seen for x-ray beams at tube voltages < or = 180 kV. No significant reduction in the relative response was seen for 137Cs and 250 kV x rays.CONCLUSIONS:When calibrated in 60Co or MV photon beams, corrections for the photon energy dependence of detector response are needed to achieve the highest accuracy when using lithium formate EPR dosimeters for measuring absorbed doses around brachytherapy sources emitting photons in the energy range of 20-150 keV such as 169Yb and electronic sources.
  •  
10.
  • Akre, Olof, et al. (författare)
  • Mortality Among Men with Locally Advanced Prostate Cancer Managed with Noncurative Intent: A Nationwide Study in PCBaSe Sweden
  • 2011
  • Ingår i: European Urology. - : Elsevier BV. - 1873-7560 .- 0302-2838. ; 60:3, s. 554-563
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: There are limited prognostic data for locally advanced prostate cancer PCa to guide in the choice of treatment. Objective: To assess mortality in different prognostic categories among men with locally advanced PCa managed with noncurative intent. Design, setting, and participants: We conducted a register-based nationwide cohort study within the Prostate Cancer DataBase Sweden. The entire cohort of locally advanced PCa included 14 908 men. After the exclusion of 2724 (18%) men treated with curative intent, 12 184 men with locally advanced PCa either with local clinical stage T3 or T4 or with T2 with serum levels of prostate-specific antigen (PSA) between 50 and 99 ng/ml and without signs of metastases remained for analysis. Measurements: We followed up the patient cohort in the Cause of Death Register for <= 11 yr and assessed cumulative incidence of PCa -specific death stratified by age and clinical characteristics. Results and limitations: The PCa -specific mortality at 8 yr of follow-up was 28% (95% confidence interval [CI], 25-32%) for Gleason score (GS) 2-6, 41% (95% CI, 38-44%) for GS 7, 52% (95% CI, 47-57%) for GS 8, and 64% (95% CI, 59-69%) for GS 9-10. Even for men aged >85 yr at diagnosis with GS 8-10, PCa was a major cause of death: 42% (95% CI, 37-47%). Men with locally advanced disease and a PSA <4 ng/ml at diagnosis were at particularly increased risk of dying from PCa. One important limitation is the lack of bone scans in 42% of the patient cohort, but results remained after exclusion of patients with unknown metastasis status. Conclusions: The PCa-specific mortality within 8 yr of diagnosis is high in locally advanced PCa, suggesting undertreatment, particularly among men in older age groups. Our results underscore the need for more studies of treatment with curative intent for locally advanced tumors. (C) 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 58
Typ av publikation
tidskriftsartikel (50)
konferensbidrag (4)
rapport (2)
doktorsavhandling (1)
bokkapitel (1)
Typ av innehåll
refereegranskat (52)
övrigt vetenskapligt/konstnärligt (6)
Författare/redaktör
Adolfsson, Jan (40)
Stattin, Pär (24)
Lambe, Mats (18)
Garmo, Hans (17)
Holmberg, Lars (14)
Bill-Axelson, Anna (14)
visa fler...
Bratt, Ola (11)
Van Hemelrijck, Miek ... (10)
Fornander, Tommy (6)
Akre, Olof (6)
Johansson, Jan-Erik (5)
Håkansson, Jan (5)
Wärnberg, Fredrik (4)
Hugosson, Jonas, 195 ... (4)
Adolfsson, Rolf (4)
Ahlgren, Johan (4)
Berglund, Anders (3)
Hogström, Lars (3)
Sogn, Jan (3)
Adolfsson, Carl-Henr ... (3)
Holmberg, Erik, 1951 (3)
Holmqvist, Marit (3)
Bergdahl, Jan (3)
Hellström, Anna-Lena ... (2)
Janson, Per-Olof, 19 ... (2)
Adami, Hans Olov (2)
Cnattingius, Sven (2)
Grönberg, Henrik (2)
Mucci, Lorelei A (2)
Nyberg, Lars (2)
Carlsson, Stefan (2)
Steineck, Gunnar, 19 ... (2)
Adolfsson, Annsofie, ... (2)
Berg, Marie, 1955 (2)
Johansson, Marianne (2)
Francis, Jynfiaf (2)
Adolfsson, Carl-Henr ... (2)
Sundberg, Daniel, 19 ... (2)
Ingelsson, Erik (2)
Norrback, Karl-Fredr ... (2)
Nilsson, Lars-Göran (2)
Del-Favero, Jurgen (2)
Sandin, Fredrik (2)
Bälter, Katarina (2)
Robinson, David (2)
Andersson, Therese M ... (2)
Bergkvist, Leif (2)
Nyberg, Ullakarin (2)
Fall, Katja (2)
Bahmanyar, Shahram (2)
visa färre...
Lärosäte
Umeå universitet (28)
Uppsala universitet (18)
Karolinska Institutet (15)
Göteborgs universitet (8)
Lunds universitet (8)
Örebro universitet (7)
visa fler...
Linnéuniversitetet (5)
Stockholms universitet (4)
Linköpings universitet (4)
Mälardalens universitet (2)
Luleå tekniska universitet (1)
Chalmers tekniska högskola (1)
Högskolan i Borås (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (55)
Svenska (3)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (42)
Samhällsvetenskap (8)
Naturvetenskap (2)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy